Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Eplerenone

Abstract

In September 2002, eplerenone (Inspra; Pharmacia), the first selective aldosterone receptor antagonist, was approved by the FDA for the treatment of hypertension. Will it become as successful as established blockbuster drugs that also target the renin–angiotensin–aldosterone system?

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Aldosterone antagonism.
Figure 2: Number of cases of hypertension.
Figure 3: Sales for antihypertensive drugs in US $ billion.

References

  1. 1

    Mosterd, A. et al. Trends in the prevalence of hypertension, antihypertension therapy, and left ventricular hypertrophy from 1950 to 1999. N. Engl. J. Med. 340, 1221–1227 (1999).

    CAS  Article  Google Scholar 

  2. 2

    Zaman, M. A., Oparil, S. & Calhoun, D. A. Drugs targeting the renin–angiotensin–aldosterone system. Nature Rev. Drug Discov. 1, 621–636 (2002).

    CAS  Article  Google Scholar 

  3. 3

    McKelvie, R. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD Pilot Study Investigators. Circulation 100, 1056–1064 (1999).

    CAS  Article  Google Scholar 

  4. 4

    Rocha, R. & Funder, J. W. The pathophysiology of aldosterone in the cardiovascular system. Ann. NY Acad. Sci. 970, 89–100 (2002).

    CAS  Article  Google Scholar 

  5. 5

    McMahon, E. G. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. 1, 190–196 (2001).

    CAS  Article  Google Scholar 

  6. 6

    Brest, A. N. Spironolactone in the treatment of hypertension: a review. Clin.Ther. 8, 568–585 (1986).

    CAS  Google Scholar 

  7. 7

    Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 (1999).

    CAS  Article  Google Scholar 

  8. 8

    de Gasparo, M. et al. Three new spironolactone deriatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. 240, 650–656 (1987).

    CAS  Google Scholar 

  9. 9

    FDA Drug Approvals List [online] (cited 27 Jan 2003). http://www.fda.gov/cder/foi/label/2002/21437lbl.pdf

  10. 10

    Quaschning, T. et al. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37, 801–805 (2001).

    CAS  Article  Google Scholar 

  11. 11

    Sica, D. A. Current concepts of pharmacotherapy in hypertension. Eplerenone: a new aldosterone receptor antagonist — are the FDA restrictions appropriate? J. Clin. Hypertens. 4, 441–445 (2002).

    CAS  Article  Google Scholar 

  12. 12

    Weinberger, M. et al. Comparison of eplerenone and losartan in patients with low-renin hypertension. Am. J. Hypertens. 15, A24 (2002).

    Article  Google Scholar 

  13. 13

    Weber, M. Clinical implications of aldosterone blockade. Am. Heart J. 144, S12–S18 (2002).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ruth Brown.

Additional information

Peter Kirkpatrick is Senior Editor of Nature Reviews Drug Discovery. Ruth Brown and Jeremy Quirk are Analysts

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Brown, R., Quirk, J. & Kirkpatrick, P. Eplerenone. Nat Rev Drug Discov 2, 177–178 (2003). https://doi.org/10.1038/nrd1039

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing